Gene Therapy News

Quant Pioneers, Experts and Investors to Discuss Rapid Market Evolution

NEW YORK – The stem cell and regenerative medicine industry is facing a serious funding problem. Just as the first therapies are reaching commercialization, biotechs in phase 2 and 3 are struggling to raise the funds needed to finish their studies. Over 300 biotechs, pharmas, investors, and suppliers will be meeting in Boston on September 20-21 at the Stem Cells USA and Regenerative Medicine Congress 2012.

Commercial development opportunities for pharma, biotech, and investors

The Stem Cells USA & Regenerative Medicine Congress is the region's largest commercial stem cells conference.

Most stem cell companies face two options - go bankrupt or find a partner with deep pockets. Despite there being hundreds of companies with promising technologies, most of them never pass Phase II trials due to lack of funding.

Clinical Data Published for a Phase I AADC-deficiency Trial Using a Gene Therapy Manufactured by Florida Biologix

ALACHUA, FL May 16, 2012 - Florida Biologix®, a full-service biopharmaceutical development and contract manufacturing organization, provided cGMP manufacturing services to National Taiwan University Hospital under a contract signed in March 2008. Florida Biologix produced, purified, and tested a clinical batch of their novel gene therapy for a Phase I clinical trial of a rare genetic disease – AADC deficiency. The trial was led by Dr. Paul Wuh-Liang Hwu. Results of the clinical trial were published in the May 16th issue of Science Translational Medicine.